Arrowhead Pharmaceuticals, Inc. (LON:0HI3)
London · Delayed Price · Currency is GBP · Price in USD 68.38
+7.40 (12.14%)
Dec 8, 2025, 3:17 PM BST
Arrowhead Pharmaceuticals Revenue
In the fiscal year ending September 30, 2025, Arrowhead Pharmaceuticals had annual revenue of $829.45M USD with 23,258.15% growth. Arrowhead Pharmaceuticals had revenue of $256.47M in the quarter ending September 30, 2025.
Revenue
$829.45M
Revenue Growth
+23,258.15%
P/S Ratio
10.15
Revenue / Employee
$1.17M
Employees
711
Market Cap
6.26B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2025 | 829.45M | 825.90M | 23,258.15% |
| Sep 30, 2024 | 3.55M | -237.18M | -98.52% |
| Sep 30, 2023 | 240.74M | -2.50M | -1.03% |
| Sep 30, 2022 | 243.23M | 104.94M | 75.89% |
| Sep 30, 2021 | 138.29M | 50.30M | 57.16% |
| Sep 30, 2020 | 87.99M | -80.80M | -47.87% |
| Sep 30, 2019 | 168.80M | 152.65M | 945.67% |
| Sep 30, 2018 | 16.14M | -15.27M | -48.60% |
| Sep 30, 2017 | 31.41M | 31.25M | 19,736.49% |
| Sep 30, 2016 | 158.33K | -223.67K | -58.55% |
| Sep 30, 2015 | 382.00K | 207.00K | 118.29% |
| Sep 30, 2014 | 175.00K | -115.27K | -39.71% |
| Sep 30, 2013 | 290.27K | 143.39K | 97.63% |
| Sep 30, 2012 | 146.88K | -149.26K | -50.40% |
| Sep 30, 2011 | 296.14K | - | - |
| Sep 30, 2010 | - | - | - |
| Sep 30, 2009 | 3.76M | 2.45M | 188.38% |
| Sep 30, 2008 | 1.30M | -2.50M | -65.69% |
| Sep 30, 2007 | 3.80M | 3.20M | 537.91% |
| Sep 30, 2006 | 595.46K | 4.78K | 0.81% |
| Sep 30, 2005 | 590.68K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.24B |
| GSK plc | 32.17B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Hikma Pharmaceuticals | 2.35B |
| Convatec Group | 1.72B |
| Genus | 672.80M |
| HUTCHMED (China) | 439.54M |
Arrowhead Pharmaceuticals News
- 4 days ago - Arrowhead (ARWR) Stock Sees 9.7% Rise Following Market Activity - GuruFocus
- 5 days ago - Arrowhead Pharmaceuticals (ARWR) Gains FDA Breakthrough Therapy Designation - GuruFocus
- 6 days ago - Arrowhead Pharmaceuticals gets FDA Breakthrough Therapy status for plozasiran - Seeking Alpha
- 6 days ago - Arrowhead (ARWR) Gains FDA Breakthrough Therapy Status for Plozasiran - GuruFocus
- 6 days ago - Arrowhead Pharma (ARWR): HC Wainwright Raises Price Target to $85 | ARWR Stock News - GuruFocus
- 6 days ago - Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia - Business Wire
- 6 days ago - Insider Sell: Mauro Ferrari Sells 8,750 Shares of Arrowhead Pharmaceuticals Inc (ARWR) - GuruFocus
- 6 days ago - Arrowhead Pharmaceuticals to Participate in Upcoming December 2025 Conferences - Business Wire